Monument Therapeutics Launches First Clinical Study of MT1988, a Novel Treatment for Cognitive Impairment Associated with Schizophrenia
Manchester, UK, 26 November 2024 Monument Therapeutics, a precision neuroscience company, today announced the first participant has been successfully dosed in its Phase I clinical study of MT1988, a novel treatment targeting cognitive impairment associated with schizophrenia (CIAS). MT1988 is a fixed-dose combination of two well-established small molecules that act on nicotinic receptors, designed to […]
Monument Therapeutics Announces Appointment of Dr Stephen Brannan, Dr Jeff Baker and Dr Mark Treherne to its Advisory Board to Guide Schizophrenia Program
Manchester, UK, 19 November 2024 Monument Therapeutics, a precision-neuroscience company focused on the development of innovative treatments for serious central nervous system disorders (CNS), is pleased to announce the addition of three distinguished experts to its Scientific Advisory Board (SAB). Leading the SAB as the new chairperson is Dr Mark Treherne, a research scientist with […]
Monument Therapeutics Secures £1M Investment To Fund Its Schizophrenia Programme And Drive Next Stage of Growth
Manchester, UK, 15 October 2024 Monument Therapeutics, a precision neuroscience company, today announced a further £1M equity investment by the Forster Foundation, a charitable incorporated organisation. The new investment builds on equity and non-dilutive funding announced in April 2024 and will support the clinical development of MT1988, a novel treatment for the cognitive symptoms of […]
Monument Therapeutics Announces Grant of UK Patent for Neuroinflammation Compound MT1980
Manchester, UK, September 17, 2024 Monument Therapeutics, a stratified medicine company developing novel treatments for areas of high unmet need in psychiatry and neurology, today announced that the United Kingdom Intellectual Property Office (“IPO”) has granted UK patent GB2616923, in support of MT1980, an anti-neuroinflammatory compound using novel brain-targeting technology. The patent, which is set to […]
Precision neuroscience company Monument Therapeutics announces £1.5m funding to kickstart schizophrenia clinical development.
Manchester, UK, and Cambridge UK, 18 April 2024 Monument Therapeutics, a precision neuroscience company, today announced new funding of £1.5 million from a combination of equity investment and non-dilutive grant as part of the Innovate UK Future Economy Investor Partnership programme. The round was led by Cambridge Angels, one of the UK’s leading business angel […]
Monument Therapeutics announces the grant of U.S. patent supporting MT1988 program for schizophrenia
Manchester, UK, January 4, 2024 – Monument Therapeutics, a stratified medicine company developing novel treatments for areas of high unmet need in psychiatry and neurology, today announced that the United States Patent and Trademark Office (“USPTO”) has granted U.S. patent 11,862,337, in support of its MT1988 program for cognitive impairment associated with schizophrenia (CIAS). The […]
Stratified neuroscience company Monument Therapeutics to present positive data for first clinical study of MT1980, a novel treatment for neuroinflammation, at AD/PD conference
Monument Tx CSO to present positive data from first-in-human clinical study for MT1980, a novel treatment for neuroinflammation, at AD/PD conference March 28th-April 1st 2023 Manchester, UK, March 27th, 2023: Monument Therapeutics, a stratified neuroscience company, today announced they will be presenting positive results from their lead clinical program at the AD/PD conference, March 28th–April […]
Stratified neuroscience company Monument Therapeutics announces first clinical study of MT1980, a novel treatment for neuroinflammation, has successfully met all objectives
Stratified neuroscience company Monument Therapeutics announces first clinical study of MT1980, a novel treatment for neuroinflammation, has successfully met all objectives Monument Tx announce first-in-human clinical study for MT1980, a novel treatment for neuroinflammation, shows drug can access the brain San Francisco, USA, January 8, 2023: Monument Therapeutics, a stratified neuroscience company, will this week […]
Monument Therapeutics presents positive preclinical data for cognitive impairment in schizophrenia programme at BAP conference
Stratified medicine company Monument Therapeutics presents positive preclinical data for cognitive impairment in schizophrenia programme at BAP conference Manchester, UK, August 02, 2022: Monument Therapeutics, a stratified medicine company, announced at the British Association for Psychopharmacology conference, positive preclinical results supporting the use of their proprietary non-invasive digital biomarker and drug MT1988 to treat […]
Stratified medicine company Monument Therapeutics announces the start of its first clinical study for MT1980, a novel treatment for neuroinflammation
Stratified medicine company Monument Therapeutics announces the start of its first clinical study for MT1980, a novel treatment for neuroinflammation Monument Tx announce first-in-human study of MT1980, a novel treatment for neuroinflammation Manchester, UK, June 13, 2022: Monument Therapeutics, a stratified medicine company, today announced that their first-in-human Phase I study of MT1980, a novel […]
Stratified medicine company Monument Therapeutics to present positive preclinical data for anti-neuroinflammation target MT1980 at AD/PD conference
Stratified medicine company Monument Therapeutics to present positive preclinical data for anti-neuroinflammation target MT1980 at AD/PD conference Monument Tx CSO to present preclinical data for lipid reformulation of anti-inflammatory compound MT1980 at AD/PD conference in Barcelona 15-20th March 2022 Manchester, UK, March 14, 2022: Monument Therapeutics, a stratified medicine company, today announced it will be […]
Stratified medicine company Monument Therapeutics to announce development of novel risk prediction tool for post-operative cognitive decline at AD/PD conference
Stratified medicine company Monument Therapeutics to announce development of novel risk prediction tool for post-operative cognitive decline at AD/PD conference Monument Tx CSO to present novel biomarker predicting risk for developing POCD at AD/PD conference in Barcelona 15-20th March 2022 Manchester, UK, March 14, 2022: Monument Therapeutics, a stratified medicine company, today announced it will […]
Stratified medicine company Monument Therapeutics raises additional £0.5 million to take anti-neuroinflammation candidate MT1980 into clinic
Stratified medicine company Monument Therapeutics raises additional £0.5 million to take anti-neuroinflammation candidate MT1980 into clinic Lipid reformulation of anti-inflammatory compound MT1980 for POCD accelerating into clinic in 2022 Manchester, UK, Dec 14, 2021: Monument Therapeutics, a stratified medicine company, today announced it has raised an additional £0.5 million to accelerate the development of its anti- neuroinflammation compound MT1980, […]
Monument Therapeutics collaborates with the University of Nottingham on pioneering schizophrenia study
Monument Therapeutics collaborates with the University of Nottingham on pioneering schizophrenia study Aim to bring novel digital biomarker-drug combination that overcomes biological heterogeneity challenge to clinic by 2022 Manchester, UK, September 20, 2021: Monument Therapeutics, a stratified medicine company, today announced a pioneering preclinical study to support the use of their proprietary non-invasive biomarker for […]
Monument Therapeutics is delighted to announce the appointment of Dr Paula Moran to its Scientific Advisory Board
Monument Therapeutics is delighted to announce the appointment of Dr Paula Moran to its Scientific Advisory Board. Paula brings deep expertise in psychopharmacology, using animal and human translational models to understand the biology of schizophrenia and Alzheimer’s disease. Following on from her PhD at the University of Ireland, Paula spent 6 years as a Scientist […]
Monument Therapeutics is delighted to announce the appointment of Dr Julian Gilbert to its Board as a Non-Executive Director
Monument Therapeutics is delighted to announce the appointment of Dr Julian Gilbert to its Board as a Non-Executive Director Julian brings deep expertise in the development and commercialising of repurposed and reprofiled compounds. He was co-founder and CEO of Acacia Pharma Group plc, a hospital pharmaceuticals company which launched its lead product BARHEMSYS®, a repurposed […]
Digital brain biomarker company Monument Therapeutics raises £2.6 million
Cambridge Cognition spin-out targets schizophrenia and post-operative cognitive dysfunction Manchester, UK, July 1st, 2021: Monument Therapeutics, a stratified medicine company, today announced it has raised £2.625 million in seed funding to spin out of Cambridge Cognition Ltd and relocate to Alderley Park, Cheshire. The new company will focus on applying digital biomarkers to neuroscience drug […]
Richard Bungay Joins the Board as a Director
Change of Director – 22nd April 2021 Monument Therapeutics is pleased to announce that Richard Bungay will join the Board as a Director with immediate effect. Mr. Bungay has over 25 years’ experience in corporate roles with R&D-based companies within the biotechnology and pharmaceutical sector, including as CFO of both public and private companies, with […]
